Brief: Vanda Pharmaceuticals Provides Regulatory Update On Tradipitant For Motion Sickness
28/11/2025 12:26
Nov 28 (Reuters) - Vanda Pharmaceuticals Inc VNDA.O: VANDA PHARMACEUTICALS PROVIDES REGULATORY UPDATE ON TRADIPITANT FOR MOTION SICKNESS VANDA PHARMACEUTICALS INC - FDA EXTENDS RE-REVIEW OF PARTIAL CLINICAL HOLD TO DEC 5, 2025 Source text: ID:nPn8p0BvRa Further company coverage: VNDA.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vanda Pharmaceuticals
See all newsUS STOCKS ON THE MOVE-Caterpillar, Kimberly-Clark, Bending Spoons
US STOCKS ON THE MOVE-Walmart, Super Micro, FMC
US STOCKS ON THE MOVE-Nvidia, Penske Automotive, ManpowerGroup
US STOCKS ON THE MOVE-Barrick Mining, Venture Global, GE Vernova
Vanda Pharma shares slip as trial failure halts anxiety drug program